Can DNA-Guided drugs outsmart tough cancers?

NCT ID NCT03089554

Recruiting now Disease control Sponsor: Rachel Miller Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study is for people with advanced cancer who have run out of standard treatment options. Researchers will analyze the genetic makeup of each patient's tumor and recommend a targeted drug therapy based on those results. The goal is to see if this personalized approach can slow cancer growth or improve outcomes. About 93 participants will be enrolled.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: targeted therapy drugs based on tumor genetic testing
What this could lead to: If successful, this could show that matching cancer treatments to a patient's tumor genetics helps control the disease longer than standard approaches.
What could go wrong: This is a small, early-phase study (93 participants) and may not prove effective for all cancer types. The targeted therapies may not work for everyone or could have side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cancer neoplasm refractory malignant neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CANCER

Contacts and locations

Locations

Markey Cancer Center, University of Kentucky
RECRUITING

Lexington, Kentucky, 40536, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.